Press releases.

Press releases 2020

Press releases 2020
December 30th 2020

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

December 16th 2020

Immutep Upscales Efti Manufacturing

December 15th 2020

Immutep Operational Update

December 10th 2020

Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

December 10th 2020

Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer

November 19th 2020

Immutep Announces Expansion of TACTI-002 Collaboration Trial

November 19th 2020

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

November 10th 2020

Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

November 9th 2020

Immutep Announces Australian Patent Grant for IMP701 Antibody

November 3rd 2020

Immutep’s TACTI-002 Data To Be Presented At Society For Immunotherapy Of Cancer 2020 Annual Meeting

October 27th 2020

Immutep AGM 2020 - Results of Meeting

October 27th 2020

Immutep AGM 2020 - Chairman's Address

October 27th 2020

Immutep AGM 2020 - CEO Marc Voigt's Presentation

October 23rd 2020

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

October 22nd 2020

Immutep Activities Report and Appendix 4C

October 21st 2020

Immutep Granted European Patent for IMP761

October 19th 2020

Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

September 18th 2020

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

September 18th 2020

Immutep Reports Improving Results from INSIGHT-004 Trial

August 31st 2020

Immutep and Monash University Receive Grant Funding for LAG-3 Project

August 26th 2020

New Data From Immutep’s Efti To Be Presented At ESMO

August 18th 2020

Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study

August 11th 2020

Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination

July 23rd 2020

Immutep Quarterly Activities Report & Appendix 4C

July 15th 2020

Immutep Announces United States Patent Grant for IMP701 Antibody

June 29th 2020

Immutep Completes Recruitment for Part A Of Phase II TACTI-002 Study

June 22nd 2020

Immutep Receives A$1,437,826 R&D Tax Incentive

June 1st 2020

Immutep Announces Improving Data from the Phase II TACTI-002 Study

June 1st 2020

Immutep Reports First Results from INSIGHT-004 Study

May 29th 2020

Immutep Receives A$3.6 Million R&D Tax Incentive from French Government

May 27th 2020

Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting

May 7th 2020

Immutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination

May 1st 2020

Immutep to Present at Virtual Healthcare Investor Conference

April 30th 2020

Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting

April 29th 2020

Immutep Completes a A$12 Million Placement to Drive Development of its Immuno-Oncology and Autoimmune Asset Pipeline

April 28th 2020

Immutep Reports Positive Phase II TACTI-002 Data

April 27th 2020

IMM - Trading Halt

April 22nd 2020

Enrollment completed for the INSIGHT-004 Study

April 20th 2020

Immutep Quarterly Activities Report & Appendix 4C

April 16th 2020

Immutep Advances Cell Line Development for IMP761

April 14th 2020

Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

April 8th 2020

Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer

March 25th 2020

Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020

March 20th 2020

Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti

March 9th 2020

Immutep Receives Second IND Approval for Efti from US FDA

February 19th 2020

Immutep Reports Positive TACTI-002 Data

February 4th 2020

Immutep to Present TACTI-002 Interim Data at German Cancer Congress

January 29th 2020

Immutep Activities Report

January 8th 2020

Immutep Expands Part C of TACTI-002 due to Positive Data